Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Mission Bio Inc. is currently active in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. This activity level indicates an ongoing effort to expand its intellectual property in this field. The 2 pending office actions are being handled by 2 distinct examiners, which provides a distribution of the workload across different individuals at the patent office.
The cases are also assigned to 2 distinct art units. This means that the company's Biotechnology & Pharmaceuticals innovations are being reviewed under the specific guidelines of 2 different administrative groups. SALMON, KATHERINE D is the busiest examiner for the portfolio, currently managing 1 pending office action.
Because SALMON, KATHERINE D is responsible for 1 of the 2 pending office actions, the company's success depends on the decisions of multiple examiners. Practitioners should be prepared to adapt their strategies to the different styles of the 2 distinct examiners. The outcome of the 2 pending office actions will be determined by how well the company addresses the specific concerns raised within each of the 2 distinct art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALMON, KATHERINE D | 1 | 42.9% | +37.7% |
| AUGER, NOAH ANDREW | 1 | 36.2% | +42.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18557408 | GENE MODIFICATION QUANTIFICATION IN SINGLE-CELL SEQUENCING | AUGER, NOAH ANDREW | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18535441 | METHOD, SYSTEM, AND APPARATUS FOR ANALYZING AN ANALYTE OF A SINGLE CELL | SALMON, KATHERINE D | — |
| 18557408 | GENE MODIFICATION QUANTIFICATION IN SINGLE-CELL SEQUENCING | AUGER, NOAH ANDREW | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18535441 | METHOD, SYSTEM, AND APPARATUS FOR ANALYZING AN ANALYTE OF A SINGLE CELL | SALMON, KATHERINE D | 1682 | §102§103§112DP | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18557408 | GENE MODIFICATION QUANTIFICATION IN SINGLE-CELL SEQUENCING | AUGER, NOAH ANDREW | 1687 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMission Bio Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Katherine D Salmon has the most, with 1 of Mission Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
